Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report
Introduction: Chemotherapy combined with anti-human epidermal growth factor receptor 2 (HER2)-targeted therapy is currently a standard treatment for advanced HER2/HR-positive breast cancer (BC), although evidences showed that HR expression compromised effectiveness of the treatment....
Saved in:
| Main Authors: | Suthida Suwanvecho, Narongsak Kiatikajornthada, Ployploen Phikulsod, Harit Suwanrusme, Siwanon Jirawatnotai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000542926 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Abemaciclib and Letrozole in Metastatic Male Breast Cancer
by: Leon Schönfeld, et al.
Published: (2024-11-01) -
Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01) -
Complete Remission of Cutaneous Metastasis from Invasive Breast Cancer with Abemaciclib plus Letrozole
by: Shaunak N. Valame, et al.
Published: (2024-02-01) -
Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01) -
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)